Investigational drug · Phase 3
KP-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Venous Malformations, Lymphatic Malformations, Klippel-Trenaunay Syndrome.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "KP-001"
First trial start
2026
May 13, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "KP-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Venous Malformations
- Lymphatic Malformations
- Klippel-Trenaunay Syndrome
- CLOVES Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "KP-001" as an intervention, largest first.
- A Study to Investigate Efficacy and Safety of KP-001 Compared With Placebo in Patients Aged ≥2 Years With Common VM, Common LM, or KTS/CLOVES SyndromePivotal-lookingRecruiting
Kaken PharmaceuticalIndustry
NCT07285005 · 150 participants (planned) · Start May 13, 2026 · Primary completion Feb 2028
Drug: KP-001; Placebo · For: Venous Malformations; Lymphatic Malformations; Klippel-Trenaunay Syndrome and 1 more
Sites: Columbia, Missouri; Chapel Hill, North Carolina; Charleston, South Carolina · 10 sites in all
Kaken PharmaceuticalIndustry
NCT06649942 · 40 participants · Start Oct 1, 2024 · Primary completion Mar 24, 2025
Drug: KP-001; KP-001 and 2 more · For: Healthy Volunteers - Male and Female
Sites: Glendale, California
Kaken PharmaceuticalIndustry
NCT06227832 · 38 participants · Start Dec 15, 2023 · Primary completion Mar 15, 2024
Drug: KP-001; Metformin and 2 more · For: Healthy Adults
Sites: Glendale, California
Kaken PharmaceuticalIndustry
NCT06821698 · 38 participants · Start Feb 13, 2025 · Primary completion May 20, 2025
Drug: KP-001; Rosuvastatin calcium10mg and 2 more · For: Healty Volunteers
Sites: Glendale, California
Kaken PharmaceuticalIndustry
NCT06619054 · 24 participants · Start Oct 24, 2024 · Primary completion May 16, 2025
Drug: KP-001 · For: Healthy Adults; Hepatic Impairment
Sites: San Antonio, Texas
Kokua Pharma Inc.Academic, hospital or other
NCT06963411 · 16 participants · Start May 9, 2025 · Primary completion Jul 18, 2025
Drug: KP001; Placebo · For: Acute Allergic Reaction; Anaphylaxis
Sites: Québec, Canada
Newest research
PubMed records naming it or its code names, newest first.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.